Yahoo
NasdaqCM - Nasdaq Real Time Price USD

P3 Health Partners Inc. (PIII)

4.0000 -0.0300 (-0.74%)
As of 2:18:34 PM EST. Market Open.
Chart Range Bar
Loading chart for PIII
  • Previous Close 4.0300
  • Open 4.0000
  • Bid 4.4000 x 200
  • Ask 9.3500 x 5700
  • Day's Range 3.9700 - 4.1600
  • 52 Week Range 1.5200 - 16.8900
  • Volume 3,867
  • Avg. Volume 32,378
  • Market Cap (intraday) 815.152M
  • Beta (5Y Monthly) 1.80
  • PE Ratio (TTM) --
  • EPS (TTM) -33.0200
  • Earnings Date Nov 9, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 18.00

P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. The company was founded in 2020 and is based in Henderson, Nevada.

p3hp.org

320

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

PIII
14.61%
S&P 500 (^GSPC)
10.74%

1-Year Return

PIII
54.29%
S&P 500 (^GSPC)
10.83%

3-Year Return

PIII
94.44%
S&P 500 (^GSPC)
75.57%

5-Year Return

PIII
99.20%
S&P 500 (^GSPC)
63.71%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 386.38M
Earnings -2.13M
Profit Margin -0.55%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
100M
200M
300M
-15.0%
-10.0%
-5.0%
0.0%

Analyst Insights

View More

Analyst Price Targets

13.00
18.00 Average
4.0000 Current
23.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/22/2026
Analyst TD Cowen
Rating Action Maintains
Rating Hold
Price Action Raises
Price Target 3 -> 14

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -6.55%

  • Return on Assets (ttm)

    -13.40%

  • Return on Equity (ttm)

    -192.58%

  • Revenue (ttm)

    1.5B

  • Net Income Avi to Common (ttm)

    -108.01M

  • Diluted EPS (ttm)

    -33.0200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    21.27M

  • Total Debt/Equity (mrq)

    94.95%

  • Levered Free Cash Flow (ttm)

    -124.25M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: